Superworth

Adma Biologics PE ratio ADMA

Share price divided by earnings per share over the last twelve months, since 2024.

Today, Nov 2, 2026
15.8×
2-year median
21.3×
Against its 2-year history
23rd
percentile: 0 is its lowest day, 100 its highest
2-year range
11.7× to 145×
Peer median
31.9×

Adma Biologics' PE ratio is 15.8× as of Nov 2, 2026: a share price of $11.06 against $0.70 of earnings per share over the last twelve months.

That is below its 2-year median of 21.3×, lower than on 77% of days in the last 2 years.

Over that time it ranged from 11.7× in Jun 2026 to 145× in Oct 2024.

The median for 10 biotech stocks of a similar size is 31.9×.

PE ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far15.8×11.7×25.9×
202522.7×16.9×66.3×
202462.3×62.1×145×

Against its peers

Companies in Biotechnology nearest Adma Biologics' size, closest first, today.

CompanyPE ratio
ADMAAdma Biologics15.8×
VCELVericel88.1×
MGTXMeiraGTx13.1×
KRYSKrystal Biotech37.1×
RGENRepligen237×
TECHBIO-TECHNE63.2×
HALOHalozyme Therapeutics38.5×
NBIXNeurocrine Biosciences21.3×
EXELExelixis22.1×
ALNYAlnylam Pharmaceuticals26.7×
INCYIncyte15.3×
Peer median31.9×

Where Adma Biologics ranks

What the PE ratio tells you

Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.

Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.

More on Adma Biologics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.